Archives of Pediatric Infectious Diseases

Published by: Kowsar

Interleukin-1 as a Key Factor in the Development of Inflammatory Diseases

Shirin Farivar 1 , 2 , Mahdieh Hassani 1 and Reza Shiari 3 , 4 , *
Authors Information
1 Department of Genetics, Faculty of Biological Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Laser and Plasma Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Department of Pediatric Rheumatology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Pediatric Infections Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Pediatric Infectious Diseases: October 01, 2014, 2 (4); e18177
  • Published Online: October 29, 2014
  • Article Type: Review Article
  • Received: February 11, 2014
  • Accepted: March 15, 2014
  • DOI: 10.5812/pedinfect.18177

To Cite: Farivar S, Hassani M, Shiari R. Interleukin-1 as a Key Factor in the Development of Inflammatory Diseases, Arch Pediatr Infect Dis. 2014 ; 2(4):e18177. doi: 10.5812/pedinfect.18177.

Copyright © 2014, Pediartric Infections Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Conclusions
  • 1. Chen HF, Shew JY, Ho HN, Hsu WL, Yang YS. Expression of leukemia inhibitory factor and its receptor in preimplantation embryos. Fertil Steril. 1999; 72(4): 713-9[PubMed]
  • 2. David F, Farley J, Huang H, Lavoie JP, Laverty S. Cytokine and chemokine gene expression of IL-1beta stimulated equine articular chondrocytes. Vet Surg. 2007; 36(3): 221-7[DOI][PubMed]
  • 3. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008; 4(1): 34-42[DOI][PubMed]
  • 4. Fritz JH, Girardin SE. How Toll-like receptors and Nod-like receptors contribute to innate immunity in mammals. J Endotoxin Res. 2005; 11(6): 390-4[DOI][PubMed]
  • 5. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A. 2007; 104(1): 282-7[DOI][PubMed]
  • 6. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol. 1998; 70: 281-312[PubMed]
  • 7. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5): 479-90[DOI][PubMed]
  • 8. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004; 20(3): 319-25[PubMed]
  • 9. Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998; 856: 1-11[PubMed]
  • 10. Martinon F, Hofmann K, Tschopp J. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr Biol. 2001; 11(4)-20[PubMed]
  • 11. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007; 14(1): 10-22[DOI][PubMed]
  • 12. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2007; 7(1): 31-40[DOI][PubMed]
  • 13. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34(9): 1158-63[PubMed]
  • 14. Dinarello CA. Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. Arthritis Rheum. 2007; 56(9): 2817-22[DOI][PubMed]
  • 15. Annand RR, Dahlen JR, Sprecher CA, De Dreu P, Foster DC, Mankovich JA, et al. Caspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem J. 1999; 342 Pt 3: 655-65[PubMed]
  • 16. Humke EW, Shriver SK, Starovasnik MA, Fairbrother WJ, Dixit VM. ICEBERG: A Novel Inhibitor of Interleukin-1β Generation. Cell. 2000; 103(1): 99-111[DOI]
  • 17. Lee SH, Stehlik C, Reed JC. Cop, a caspase recruitment domain-containing protein and inhibitor of caspase-1 activation processing. J Biol Chem. 2001; 276(37): 34495-500[DOI][PubMed]
  • 18. Azam T, Novick D, Bufler P, Yoon DY, Rubinstein M, Dinarello CA, et al. Identification of a critical Ig-like domain in IL-18 receptor alpha and characterization of a functional IL-18 receptor complex. J Immunol. 2003; 171(12): 6574-80[PubMed]
  • 19. Kato Z, Jee J, Shikano H, Mishima M, Ohki I, Ohnishi H, et al. The structure and binding mode of interleukin-18. Nat Struct Biol. 2003; 10(11): 966-71[DOI][PubMed]
  • 20. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A. 2000; 97(3): 1190-5[PubMed]
  • 21. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999; 10(1): 127-36[PubMed]
  • 22. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001; 14(6): 334-42[DOI][PubMed]
  • 23. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999; 104(10): 1393-401[DOI][PubMed]
  • 24. Maeno N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum. 2002; 46(9): 2539-41[DOI][PubMed]
  • 25. Farivar S, Shiari R, Hadi E. Molecular analysis of MEFV gene in Iranian children with Familial Mediterranean fever. Indian J Rheumatology. 2010; 5(2): 66-8[DOI]
  • 26. Diaz A, Hu C, Kastner DL, Schaner P, Reginato AM, Richards N, et al. Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-terminal domain that is highly mutated in familial Mediterranean fever. Arthritis Rheum. 2004; 50(11): 3679-89[DOI][PubMed]
  • 27. Fairbrother WJ, Gordon NC, Humke EW, O'Rourke KM, Starovasnik MA, Yin JP, et al. The PYRIN domain: a member of the death domain-fold superfamily. Protein Sci. 2001; 10(9): 1911-8[DOI][PubMed]
  • 28. Kohl A, Grutter MG. Fire and death: the pyrin domain joins the death-domain superfamily. C R Biol. 2004; 327(12): 1077-86[PubMed]
  • 29. Masumoto J, Taniguchi S, Ayukawa K, Sarvotham H, Kishino T, Niikawa N, et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem. 1999; 274(48): 33835-8[PubMed]
  • 30. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006; 103(26): 9982-7[DOI][PubMed]
  • 31. Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007; 14(8): 1457-66[DOI][PubMed]
  • 32. Hall MW, Gavrilin MA, Knatz NL, Duncan MD, Fernandez SA, Wewers MD. Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ dysfunction syndrome. Pediatr Res. 2007; 62(5): 597-603[DOI][PubMed]
  • 33. Still GF. On a Form of Chronic Joint Disease in Children. Med Chir Trans. 1897; 80: 47-60 9[PubMed]
  • 34. Farivar S, Shiari R, Hadi E. Genetic susceptibility to juvenile idiopathic arthritis in Iranian children. Arch Med Res. 2011; 42(4): 301-4[DOI][PubMed]
  • 35. Glass DN, Giannini EH. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum. 1999; 42(11): 2261-8[PubMed]
  • 36. Shiari R, Farivar S, Dehghan Tezerjani M. Molecular analysis of HLA-DRB1 alleles in Iranian children with juvenile systemic lupus erythematosus. Pediatr Res. 2013; 11: 296[DOI]
  • 37. Thomson W, Barrett JH, Donn R, Pepper L, Kennedy LJ, Ollier WE, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford). 2002; 41(10): 1183-9[PubMed]
  • 38. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006; 2(1): 28-34[DOI][PubMed]
  • 39. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998; 351(9107): 969-73[DOI]
  • 40. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998; 25(10): 1991-4[PubMed]
  • 41. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31(2): 390-2[PubMed]
  • 42. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005; 201(9): 1479-86[DOI][PubMed]
  • 43. De Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007; 66(5): 589-98[DOI][PubMed]
  • 44. Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. 2001; 44(3): 550-60[PubMed]
  • 45. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med. 2005; 201(9): 1355-9[DOI][PubMed]
  • 46. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001; 29(3): 301-5[DOI][PubMed]
  • 47. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol. 2003; 4(2): 95-104[DOI][PubMed]
  • 48. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today. 1994; 15(12): 562-6[DOI][PubMed]
  • 49. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003; 18(1): 87-96[PubMed]
  • 50. De Jager W, Vastert SJ, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients. Pediatr Rheumatol. 2011; 9[DOI]
  • 51. Hedrich CM, Bruck N, Fiebig B, Gahr M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int. 2012; 32(11): 3525-30[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments